32 studies found for:    Open Studies | "Plasmacytoma"
Show Display Options
Rank Status Study
21 Unknown  Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: platelet aggregation test
22 Unknown  Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone
23 Unknown  Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Conditions: Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Neuroblastoma;   Oral Complications;   Ovarian Cancer;   Pain;   Sarcoma
Interventions: Procedure: management of therapy complications;   Procedure: pain therapy
24 Recruiting Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
25 Unknown  Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: melphalan;   Drug: pegylated liposomal doxorubicin hydrochloride
26 Unknown  Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: rasburicase;   Drug: sirolimus;   Drug: tacrolimus;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunologic technique;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
27 Unknown  Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
Condition: Cancer
Interventions: Drug: ketamine hydrochloride;   Other: pharmacogenomic studies;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: quality-of-life assessment
28 Recruiting Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: VELCADE (Bortezomib);   Drug: Dexamethasone
29 Recruiting Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
Condition: Carcinoma
Intervention:
30 Unknown  Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: CX-4945
31 Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention: Procedure: Stem cell transplantation
32 Recruiting Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Following Lenalidomide Plus Low Dose Dexamethasone as Second Line Treatment.
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-32) Next Page   
Indicates status has not been verified in more than two years